This Article Full Text Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bovill, E. G. Articles by Mann, K. G. Search for Related Content PubMed PubMed Citation Articles by Bovill, E. G. Articles by Mann, K. G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB BIOTIN

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1995;15:754-758.)
© 1995 American Heart Association, Inc.

Articles

Evidence That Meizothrombin Is an Intermediate Product in the Clotting of Whole Blood

Edwin G. Bovill; Russell P. Tracy; Timothy E. Hayes; Richard J. Jenny; Francis H. Bhushan; Kenneth G. Mann

From the Departments of Pathology (E.G.B., R.P.T., T.E.H., F.H.B.) and Biochemistry (R.J.J., K.G.M.), University of Vermont College of Medicine, Burlington.

Correspondence to Dr Edwin G. Bovill, Chairman, Department of Pathology, University of Vermont College of Medicine, Burlington, VT 05405.

Abstract Meizothrombin is an intermediate that is produced during the conversion of prothrombin to thrombin in systems composed of purified factor Xa and factor Va that are quantitatively assembled on an anionic phospholipid surface. The biological significance of this intermediate has recently been challenged by the apparent absence of meizothrombin during clotting of sodium citrate–anticoagulated plasma. We analyzed the formation of thrombin during coagulation of nonanticoagulated, unchilled, minimally manipulated whole blood in glass tubes. The process was stopped at 0, 3, 5, and 7 minutes by the addition of biotinylated peptidyl chloromethylketone active-site labeling reagents. Plasma/serum was separated by centrifugation, and labeled species were extracted by immunoadsorption with a polyclonal anti-prothrombin antibody. The purified prothrombin-derived species were separated by SDS–polyacrylamide gradient gel electrophoresis and visualized on a chemiluminescent avidin blot. Meizothrombin appeared as an intermediate product of this reaction and persisted with some increase through the 7-minute time point. We also observed incorporation of the active-site label into a species of lower molecular weight consistent with the B₁ chain of ß- and/or -thrombin. These degraded forms of thrombin have not been previously demonstrated in a biologically relevant preparation. Our data clearly establish the generation of meizothrombin as an intermediate product of thrombin generation during whole-blood clotting. The data also represent the first experimental evidence for the generation of ß- and -thrombin in a biologically relevant environment and time scale.

Key Words: thrombosis • meizothrombin • coagulation • whole blood

This article has been cited by other articles:

				R. A. Saad, G. M. Arepally, and T. L. Ortel Heparin-Induced Thrombocytopenia N. Engl. J. Med., December 14, 2006; 355(24): 2598 - 2599. [Full Text] [PDF]

				M. A. Bukys, T. Orban, P. Y. Kim, D. O. Beck, M. E. Nesheim, and M. Kalafatis The Structural Integrity of Anion Binding Exosite I of Thrombin Is Required and Sufficient for Timely Cleavage and Activation of Factor V and Factor VIII J. Biol. Chem., July 7, 2006; 281(27): 18569 - 18580. [Abstract] [Full Text] [PDF]

				T. Orfeo, N. Brufatto, M. E. Nesheim, H. Xu, S. Butenas, and K. G. Mann The Factor V Activation Paradox J. Biol. Chem., May 7, 2004; 279(19): 19580 - 19591. [Abstract] [Full Text] [PDF]

				H. Koike, D. Okuda, and T. Morita Mutations in Autolytic Loop-2 and at Asp554 of Human Prothrombin That Enhance Protein C Activation by Meizothrombin J. Biol. Chem., April 18, 2003; 278(17): 15015 - 15022. [Abstract] [Full Text] [PDF]

				R. Linder, J. Oldgren, N. Egberg, L. Grip, G. Larson, A. Siegbahn, and L. Wallentin The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease Eur. Heart J., April 1, 1999; 20(7): 506 - 518. [Abstract] [PDF]

				J.-H. Han, H. C. F. Cote, and D. M. Tollefsen Inhibition of Meizothrombin and Meizothrombin(desF1) by Heparin Cofactor II J. Biol. Chem., November 7, 1997; 272(45): 28660 - 28665. [Abstract] [Full Text] [PDF]

				T. V. Byzova and E. F. Plow Networking in the Hemostatic System. INTEGRIN alpha IIbbeta 3 BINDS PROTHROMBIN AND INFLUENCES ITS ACTIVATION J. Biol. Chem., October 24, 1997; 272(43): 27183 - 27188. [Abstract] [Full Text] [PDF]

				H. C.F. Cote, L. Bajzar, W. K. Stevens, J. A. Samis, J. Morser, R. T.A. MacGillivray, and M. E. Nesheim Functional Characterization of Recombinant Human Meizothrombin and Meizothrombin(desF1). THROMBOMODULIN-DEPENDENT ACTIVATION OF PROTEIN C AND THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI), PLATELET AGGREGATION, ANTITHROMBIN-III INHIBITION J. Biol. Chem., March 7, 1997; 272(10): 6194 - 6200. [Abstract] [Full Text] [PDF]